NASDAQ · AGEN
Agenus Inc.
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
Loading market information…
NASDAQ · ABOS · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Acumen Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 36.39% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Acumen Pharmaceuticals, Inc.’s next earnings report is currently expected on Mar 25, 2027, with estimated earnings per share of -$0.32. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Acumen Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 13, 2025 |
| -$0.48+14.29% vs estimate |
| $0.00 |
| Q4 2024 | Mar 27, 2025 | -$0.62-31.91% vs estimate | $0.00 |
|---|
KEEP COMPARING
$7.09-$0.04 (-0.56%)
Agenus Inc.’s quoted price sits in the upper half of its reported 52-week range, 31.23% below the high.
$3.65-$0.03 (-0.82%)
Opus Genetics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.37% below the high.
$2.17$0.00 (0.0%)
Fate Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.82% below the high.
$2.24-$0.01 (-0.44%)
Alector, Inc.’s quoted price sits in the upper half of its reported 52-week range, 18.84% below the high.
$1.94-$0.05 (-2.51%)
Seer, Inc.’s quoted price sits in the lower half of its reported 52-week range, 18.49% below the high.
$1.11-$0.06 (-5.13%)
Spero Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.96% below the high.
$0.77-$0.16 (-16.89%)
Inovio Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 71.63% below the high.
$1.95+$0.16 (+8.94%)
Seres Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
